Trials
2 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Mucopolysaccharidosis IIIB, Mucopolysaccharidosis III-B
- Main trialPhase 1/2
- “This is a global, open-label, Phase I/II, interventional trial in participants younger than 6 years of age with Mucopolysaccharidosis Type IIIB (MPS IIIB), designed to assess the safety and tolerability of JR-446, determine its pharmacodynamic effects, and explore its potential to demonstrate early clinical effects on disease-relevant outcomes.”In the company’s words, NCT07640984 on ClinicalTrials.gov
Other drugs for Mucopolysaccharidosis III-B
Coming up2
- 30 Jun 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Apr 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Jun 2028 | A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB) | |
| Phase 1/2Active, not recruiting | 30 Apr 2030 | An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026